Melvin LK Chua: The mutational landscape of Radioresistant Cancers
Melvin LK Chua, Clinician-Scientist at the NCCS and Duke-NUS Medical School, posted on X about recent paper by him as co-author, titled “Genomic and transcriptomic profiling of radioresistant prostate and head and neck cancers implicate a BAHD1-dependent modification of DNA damage at the heterochromatin” published on Nature.
Authors: Chaw Yee Beh, Celestia Pei Xuan Yeo, Boon Hao Hong, Evelyn Mui Cheng Tan, Kah Min Tan, Dennis Jun Jie Poon, Pek Lim Chu, Dewi Susanti, Pei Ling Tai, Monica Ryu, James Proudfoot, Eugenia Li Ling Yeo, Khee Chee Soo, Melvin L. K. Chua
“Just in time for Xmas.
Pleased to share 5y of work from Chua Lab on the mutational landscape of Radioresistant Cancers.
We show that BAHD1-heterochromatin modification dominates for acquired RTresistance.
Opportunities for new targets!
This was the study schema where through clonal selection and repopulation we derive these persistent RR phenotypes.
Interestingly both protein and transcriptome showed an activated heterochromatin pathway enriched in RR cancers. We found that BAHD1 was overexpressed in our Prostate Cancer and Head and Neck Cancer models that is also implicated in chromatin remodeling.
Targeting BAHD1 reversed the radioresistance phenotype primarily through targeting the activation of heterochromatin.
Finally we posit a model where BAHD1-dependent remodelling of HC may drive radioresistance through modifying DNA repair pathways including MMR and NHEJ Data is publicly available for collaboration!”
Dr. Melvin L.K. Chua is a Clinician-Scientist at the NCCS and Duke-NUS Medical School, and Principal Investigator of the Precision Radiotherapeutics and Oncology Programme, Division of Medical Sciences, supported by the NMRC Clinician-Scientist Award. He is also the Head of Department and Senior Consultant for Head and Neck and Thoracic Cancers, Division of Radiation Oncology, and Director of the Data and Computational Science Core at the NCCS. His research is focused on phase 2-3 trials in nasopharynx (NPC) and prostate cancers (PCa).
He is also on the scientific advisory board for the NPC Guangzhou-Singapore Trial Network, a board member on the Head Neck Cancer International Group (HNCIG), and the Clinical Trials Scientific Committee Chair of HNCIG. Dr. Chuaam’s other academic activities include his present role as the Editor-in-Chief, Annals of Nasopharynx Cancer and his previous role as the Associate Senior Editor for the Head and Neck Cancer Section of the International Journal of Radiation Oncology Biology Physics – Official journal of the American Society of Radiation Oncology.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023